Spectrum Begins Phase III ZEST Study - Analyst Blog NASDAQ The study aims to evaluate the product in patients suffering from diffuse large B-cell lymphoma (DLBCL) and who are in remission after R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). The study aims to ... Spectrum initiates patient enrollment in Phase III B-cell lymphoma trial |
